Possible scenario
Reshoring Wave Accelerates
20% Chance
The Bayer project becomes part of a larger U.S. pharmaceutical reshoring cycle driven by tariff risk, supply-chain security, and federal procurement preferences. This outcome produces a broader industry read-through than the single campus announcement.
Secondary impacts
- Healthcare +0.5%
- Industrials +0.5%
- Non-Energy Materials +0.2%
Tickers
- MRK+0.8%
Portfolio impact
S&P 500+0.1%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.